ShareProphets : tidm

ELIX

Elixirr International – a trading opportunity Buy?

Despite a latest update announcement having included “Q2 2026 also delivered record quarterly revenue, resulting in H1 26 revenue of £89.0m, up 25% on H1 25… H1 26 Adjusted EBITDA increased 29% to £27.6m”, shares in this company are down from 860p early this year to 630p to buy. The following is why we consider that a trading opportunity Buy.

By HotStockRockets | Published 2026-09-05 18:15:38 |

Elixirr International (#ELIX) – “Q2 2026 also delivered record quarterly revenue”, appointment of Canaccord Genuity as joint broker

2026-08-03 06:39:56

Elixirr International (#ELIX) – 2025 adj. EPS up to 58.7p, DPS to 22.6p, “confident in its ability to deliver sustainable growth”

2026-04-20 06:40:19

Elixirr International (#ELIX) – acquisition of Denmark-based consultancy Kvadrant for initial DKK107.6m and up to further DKK47.3m

2026-02-02 07:32:56

Elixirr International (#ELIX) – H1 adj. EPS up to 31.7p, acquisition of US strategy firm TRC Advisory for up to $125m

2025-09-22 06:41:53

Elixirr International (#ELIX) – H1 organic revenue +17% YoY, confident of FY results “in line with market expectations”

2025-07-14 06:41:34

Elixirr International (#ELIX) – 2024 adj. EPS up to 43.1p, DPS to 17.8p, “intent to move to the Main Market”

2025-04-28 06:36:09

Elixirr International (#ELIX) – expects 2024 “above market expectations, “momentum has continued into 2025 with record revenue for January”

2025-02-18 07:42:57

Elixirr International (#ELIX) – acquisition of US-based “insights and strategy” business Hypothesis Group for initial $37.3m in cash and shares and up to further $7.6m

2024-10-21 06:29:50

Elixirr International (#ELIX) – H1 adj. EPS up to 21.5p, “strong momentum has continued” in line with expectations

2024-09-23 06:27:38

Elixirr International (#ELIX) – 2023 adj. EPS +22% to 37.2p, DPS +37% to 14.8p, “momentum has continued into FY24”

2024-04-22 06:27:53

Elixirr (#ELIX) – announces interim dividend, expects 2023 “in line with market expectations”

2024-01-08 07:22:38

Elixirr International (#ELIX) – acquisition of US consultancy business Insigniam for initial $13.1m in cash and shares and up to $18.5m

2023-12-11 07:25:17

previous 0 Page 1 of 1 (13 articles) next 0

Latest News

Show All

UPDATED: Lucian Miers & Jim Mellon are coming back to Sharestock in 2027: early bird tickets now on sale, event 15% sold out!

Tom Winnifrith Bearcast: the Sydney Sweeney row with the Mrs and daughter 2

Evil Banksta weighs in on TekCapital after today’s spooftastic RNS

Good news travels fast but bad news….the case of Skinbiotherapeutics

Mothercare: the end is nigh, don’t blame Trump, I told y’all eons ago

EXPOSE: Nuburu shares in a slump post relisting on American Stock Exchange and latest accounts contain a material error

Letter to Pointon Young, former auditors to Amazing AI

Reinvesting my Satsuma Winnings

Tribal Group – “Proposed Acquisition by Main Capital Partners” provides us with another share tip winner

Quantum Data Energy - why are its shares still suspended?

Recent Comments

TOYIN18 Sep 2026

Thanks Tom, just picked some more up sub 8p.

Good news travels fast but bad news….the case of Skinbiotherapeutics

JOHN BROWN18 Sep 2026

It's outrageous that the likes of Amy Hunt claim that women with Sydney Sweeney's body shape cannot play sport. Who said that sportswomen can't look like Ms Sweeney?

Tom Winnifrith Bearcast: the Sydney Sweeney row with the Mrs and daughter 2

MICKTHELINGE18 Sep 2026

If it gets to 3p then construction will be going well and it will be well on the way to 6p+ so interested in why you would sell out then?

Reinvesting my Satsuma Winnings

TOM18 Sep 2026

Whatever Opti's intentions it will have to sell.You could say you should sell now as maybe your last chance to sell at above 8oops too late, now 7.5p to sell

Good news travels fast but bad news….the case of Skinbiotherapeutics

DUCKnDIVE18 Sep 2026

I thought that a seasoned reader of financial statements would have clocked that OPTI's HY results to 30/6/26 classed their SBTX shares as non-current assets – meaning that management has no intention to sell them within 12 months.Maybe you assumed that they were forced to class them as non-current because SBTX shares were suspended…but no, the SBTX suspension was lifted weeks before OPTI's sign-off date.And if you believe that OPTI haven't sold all or most of their remaining SBTX shares since June 30th, I'm afraid they saw you coming.There is of course a risk that OPTI has double accounted for its SBTX shares, having included them in both non-current assets and in "cash and equivalents", which might be a fruitful line of enquiry for you.As for Skin's RNS arriving a day outside the standard 10th-20th definition of mid-month, they have had a lot of balls to juggle so a 24hr delay ought to be a cause for congratulations.Why not grab some SBTX shares this afternoon? Could be your last chance to buy back below 12p.

Good news travels fast but bad news….the case of Skinbiotherapeutics

DUCKnDIVE18 Sep 2026

Notwithstanding your ad nauseam negativity on SBTX, I choose to believe the positive indications from the 8 June RNS, including "Growth continued across the company", under Current Trading and Outlook (from a chairman who never speaks with forked tongue). Accordingly, I have helped myself to a nice top-up in anticipation of a welcome trading update on Monday.

Tom Winnifrith Bearcast: Hang on for the PS in the podcast

BOBINS18 Sep 2026

lets hope the Houthis keep away from the Saudi Mines?

Reinvesting my Satsuma Winnings

Charles18 Sep 2026

Easy work for the FCA with you having laid it out.

EXPOSE: Paul Mathieson and the strike off: you might think that, I could not comment

TOM18 Sep 2026

darren has done something , really working now

Tom Winnifrith Bearcast: Hang on for the PS in the podcast

ZEDBEEKAY17 Sep 2026

I can't play it either - I'm on a laptop, and it either refuses to play or gets a few minutes in and stops